Clinical Trials
194 trialsNCT02386800 2026-05-27
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
NCT07218341 2026-05-22
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 4 Recruiting
NCT03023631 2026-05-20
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
NCT06651970 2026-05-18
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
NCT07590648 2026-05-15
E-STOP2
Hospital Universitari Vall d'Hebron Research Institute
Phase 4 Not yet recruiting
NCT07044687 2026-05-12
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
AbbVie
Phase 4 Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04745910 2026-05-06
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 4 Completed
NCT06289673 2026-05-01
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
Phase 4 Recruiting
NCT07561892 2026-05-01
AML
Fujian Medical University Union Hospital
Phase 4 Recruiting
NCT06427811 2026-04-17
ASC4INDIA
Novartis
Phase 4 Completed
NCT07486713 2026-03-20
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
Phase 4 Recruiting
NCT06035757 2026-03-03
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
Konkuk University Medical Center
Phase 4 Recruiting
NCT06370000 2026-03-02
REMAIN1
Virginia Commonwealth University
Phase 4 Recruiting
NCT06876649 2026-03-02
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
Phase 4 Recruiting
NCT06876662 2026-03-02
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4 Recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT04673175 2026-01-21
Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
Weill Medical College of Cornell University
Phase 4 Terminated
NCT07320534 2026-01-08
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Gadjah Mada University
Phase 4 Not yet recruiting
NCT04296305 2025-12-26
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
NCT04952766 2025-12-23
EREVA
Centre Hospitalier Régional d'Orléans
Phase 4 Completed
NCT05687032 2025-12-03
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 4 Completed
NCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
NCT07016165 2025-08-22
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Gadjah Mada University
Phase 4 Recruiting
NCT07105319 2025-08-22
ROPEG
Eulji University Hospital
Phase 4 Completed
NCT05144243 2025-08-12
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
AbbVie
Phase 4 Active not recruiting
NCT03190330 2025-05-25
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Johnson & Johnson Private Limited
Phase 4 Completed
NCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
NCT05071482 2025-05-01
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Terminated
NCT06918054 2025-04-09
Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia
Ain Shams University
Phase 4 Recruiting
NCT06918080 2025-04-09
Hepatoprotective Measures for Children at High Risk of NAFLD
Ain Shams University
Phase 4 Active not recruiting
NCT03844360 2025-03-30
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Shandong University
Phase 4 Recruiting
NCT06763666 2025-01-08
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Nanfang Hospital, Southern Medical University
Phase 4 Not yet recruiting
NCT06711679 2024-12-02
Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia
Tongji Hospital
Phase 4 Enrolling by invitation
NCT04930536 2024-11-22
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
AstraZeneca
Phase 4 Completed
NCT02926586 2024-10-01
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4 Completed
NCT05784844 2024-09-19
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
Phase 4 Withdrawn
NCT06582186 2024-09-03
VORIPRECI
University Hospital, Grenoble
Phase 4 Not yet recruiting
NCT06571825 2024-08-26
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Zhejiang University
Phase 4 Recruiting
NCT06410833 2024-05-16
BRRPJS
Peking Union Medical College Hospital
Phase 4 Recruiting
NCT05926063 2024-03-08
SAFE
Universitaire Ziekenhuizen KU Leuven
Phase 4 Recruiting
NCT04846855 2024-02-12
RATAPED
Ramsay Générale de Santé
Phase 4 Completed
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT03677596 2023-11-22
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
Phase 4 Completed
NCT04790045 2023-10-03
LymBIO
IRCCS San Raffaele
Phase 4 Not yet recruiting
NCT05061654 2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4 Withdrawn
NCT03043430 2023-04-25
Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients
Brooke Army Medical Center
Phase 4 Terminated
NCT00198978 2023-03-20
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Goethe University
Phase 4 Completed
NCT00199056 2023-03-20
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
Goethe University
Phase 4 Completed
NCT00199095 2023-03-20
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
Goethe University
Phase 4 Completed